Diabetes and pancreatic cancer: recent insights with implications for early diagnosis, treatment and prevention

Curr Opin Gastroenterol. 2021 Sep 1;37(5):539-543. doi: 10.1097/MOG.0000000000000763.

Abstract

Purpose of review: Recent insights into the complex relationship between diabetes and pancreatic cancer have the potential to help direct future approaches to early detection, treatment and prevention.

Recent findings: Insulin resistance and hyperinsulinemia have been identified as factors that relate to risk of pancreatic cancer among patients with long-standing diabetes. In contrast, weight loss in the setting of new-onset diabetes can help identify patients at an increased risk for harbouring pancreatic-cancer related disturbances in glucose metabolism. Insights into the implications of poor glycaemic control in patients undergoing resection for pancreatic cancer have the potential to improve both surgical and oncologic outcomes. Finally, among antidiabetic medications, metformin continues to be evaluated as a potential adjunctive therapeutic agent, although recent evidence supports the safety of incretins with respect to pancreatic cancer.

Summary: This review highlights recent developments in these areas with an emphasis on opportunities for improved early diagnosis, treatment and prevention in pancreatic cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Diabetes Mellitus, Type 2*
  • Early Detection of Cancer
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Metformin* / therapeutic use
  • Pancreatic Neoplasms* / diagnosis
  • Pancreatic Neoplasms* / prevention & control

Substances

  • Hypoglycemic Agents
  • Metformin